Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma

Ming Hsien Chien, Kun Tu Yeh, Yi Ching Li, Yi Hsien Hsieh, Chien-Huang Lin, Meng Shih Weng, Wu Hsien Kuo, Shun Fa Yang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background and Objectives Hepatocellular carcinoma (HCC) is one of the most frequent malignant neoplasms worldwide, and is the second leading cause of cancer death in Taiwan. E-cadherin is an epithelial cell adhesion molecule, and decreased E-cadherin expression in HCC is associated with a poor prognosis. This study investigates the effects of single nucleotide polymorphisms (SNPs) in the E-cadherin/CDH1 gene promoter on the risk and clinicopathological characteristics of HCC Methods 131 HCC patients and 347 controls were recruited for this study. Genetic polymorphisms of CDH1-160 and-347 were analyzed by PCR-RFLP genotyping analysis. Results After adjusting for other confounders, results show that individuals with the CDH1-347G/GA or GA/GA polymorphic genotypes had a significantly higher risk of developing HCC than those with the wild-type (G/G) genotype (adjusted odds ratio=2.477; 95%CI: 1.421-4.319). Furthermore, patients with HCC with at least one mutant A allele of CDH1-160 had a 4.031-fold risk of progressing to stage III or IV. Conclusions This study shows that SNPs in CDH1-347 gene are associated with an increased risk of HCC, and at least one mutant A allele of CDH1-160 gene is associated with the development of stage III or IV of HCC in Taiwanese.

Original languageEnglish
Pages (from-to)299-304
Number of pages6
JournalJournal of Surgical Oncology
Volume104
Issue number3
DOIs
Publication statusPublished - Sep 1 2011

Fingerprint

Cadherins
Hepatocellular Carcinoma
Genes
Single Nucleotide Polymorphism
Alleles
Genotype
Genetic Polymorphisms
Taiwan
Restriction Fragment Length Polymorphisms
Cause of Death
Neoplasms
Odds Ratio
Polymerase Chain Reaction

Keywords

  • E-cadherin
  • genetic polymorphism
  • hepatocellular carcinoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma. / Chien, Ming Hsien; Yeh, Kun Tu; Li, Yi Ching; Hsieh, Yi Hsien; Lin, Chien-Huang; Weng, Meng Shih; Kuo, Wu Hsien; Yang, Shun Fa.

In: Journal of Surgical Oncology, Vol. 104, No. 3, 01.09.2011, p. 299-304.

Research output: Contribution to journalArticle

Chien, Ming Hsien ; Yeh, Kun Tu ; Li, Yi Ching ; Hsieh, Yi Hsien ; Lin, Chien-Huang ; Weng, Meng Shih ; Kuo, Wu Hsien ; Yang, Shun Fa. / Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma. In: Journal of Surgical Oncology. 2011 ; Vol. 104, No. 3. pp. 299-304.
@article{6797d7e4c16a466bb040f753710d8e54,
title = "Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma",
abstract = "Background and Objectives Hepatocellular carcinoma (HCC) is one of the most frequent malignant neoplasms worldwide, and is the second leading cause of cancer death in Taiwan. E-cadherin is an epithelial cell adhesion molecule, and decreased E-cadherin expression in HCC is associated with a poor prognosis. This study investigates the effects of single nucleotide polymorphisms (SNPs) in the E-cadherin/CDH1 gene promoter on the risk and clinicopathological characteristics of HCC Methods 131 HCC patients and 347 controls were recruited for this study. Genetic polymorphisms of CDH1-160 and-347 were analyzed by PCR-RFLP genotyping analysis. Results After adjusting for other confounders, results show that individuals with the CDH1-347G/GA or GA/GA polymorphic genotypes had a significantly higher risk of developing HCC than those with the wild-type (G/G) genotype (adjusted odds ratio=2.477; 95{\%}CI: 1.421-4.319). Furthermore, patients with HCC with at least one mutant A allele of CDH1-160 had a 4.031-fold risk of progressing to stage III or IV. Conclusions This study shows that SNPs in CDH1-347 gene are associated with an increased risk of HCC, and at least one mutant A allele of CDH1-160 gene is associated with the development of stage III or IV of HCC in Taiwanese.",
keywords = "E-cadherin, genetic polymorphism, hepatocellular carcinoma",
author = "Chien, {Ming Hsien} and Yeh, {Kun Tu} and Li, {Yi Ching} and Hsieh, {Yi Hsien} and Chien-Huang Lin and Weng, {Meng Shih} and Kuo, {Wu Hsien} and Yang, {Shun Fa}",
year = "2011",
month = "9",
day = "1",
doi = "10.1002/jso.21929",
language = "English",
volume = "104",
pages = "299--304",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma

AU - Chien, Ming Hsien

AU - Yeh, Kun Tu

AU - Li, Yi Ching

AU - Hsieh, Yi Hsien

AU - Lin, Chien-Huang

AU - Weng, Meng Shih

AU - Kuo, Wu Hsien

AU - Yang, Shun Fa

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background and Objectives Hepatocellular carcinoma (HCC) is one of the most frequent malignant neoplasms worldwide, and is the second leading cause of cancer death in Taiwan. E-cadherin is an epithelial cell adhesion molecule, and decreased E-cadherin expression in HCC is associated with a poor prognosis. This study investigates the effects of single nucleotide polymorphisms (SNPs) in the E-cadherin/CDH1 gene promoter on the risk and clinicopathological characteristics of HCC Methods 131 HCC patients and 347 controls were recruited for this study. Genetic polymorphisms of CDH1-160 and-347 were analyzed by PCR-RFLP genotyping analysis. Results After adjusting for other confounders, results show that individuals with the CDH1-347G/GA or GA/GA polymorphic genotypes had a significantly higher risk of developing HCC than those with the wild-type (G/G) genotype (adjusted odds ratio=2.477; 95%CI: 1.421-4.319). Furthermore, patients with HCC with at least one mutant A allele of CDH1-160 had a 4.031-fold risk of progressing to stage III or IV. Conclusions This study shows that SNPs in CDH1-347 gene are associated with an increased risk of HCC, and at least one mutant A allele of CDH1-160 gene is associated with the development of stage III or IV of HCC in Taiwanese.

AB - Background and Objectives Hepatocellular carcinoma (HCC) is one of the most frequent malignant neoplasms worldwide, and is the second leading cause of cancer death in Taiwan. E-cadherin is an epithelial cell adhesion molecule, and decreased E-cadherin expression in HCC is associated with a poor prognosis. This study investigates the effects of single nucleotide polymorphisms (SNPs) in the E-cadherin/CDH1 gene promoter on the risk and clinicopathological characteristics of HCC Methods 131 HCC patients and 347 controls were recruited for this study. Genetic polymorphisms of CDH1-160 and-347 were analyzed by PCR-RFLP genotyping analysis. Results After adjusting for other confounders, results show that individuals with the CDH1-347G/GA or GA/GA polymorphic genotypes had a significantly higher risk of developing HCC than those with the wild-type (G/G) genotype (adjusted odds ratio=2.477; 95%CI: 1.421-4.319). Furthermore, patients with HCC with at least one mutant A allele of CDH1-160 had a 4.031-fold risk of progressing to stage III or IV. Conclusions This study shows that SNPs in CDH1-347 gene are associated with an increased risk of HCC, and at least one mutant A allele of CDH1-160 gene is associated with the development of stage III or IV of HCC in Taiwanese.

KW - E-cadherin

KW - genetic polymorphism

KW - hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=80051503331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051503331&partnerID=8YFLogxK

U2 - 10.1002/jso.21929

DO - 10.1002/jso.21929

M3 - Article

C2 - 21462191

AN - SCOPUS:80051503331

VL - 104

SP - 299

EP - 304

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -